Alamar Biosciences 的 NULISA 數據將於 AAIC 2026 上超過 140 場科學簡報會中亮相，突顯基於血液的阿茲海默症生物標記剖析之最新進展

Alamar Biosciences announced that its NULISA platform will be featured in over 140 posters and presentations at the Alzheimer's Association International Conference (AAIC) in London. The company highlighted advances in blood-based biomarker profiling, particularly the eMTBR-Tau and BD-pTau217 tests, which can be measured simultaneously with 220+ CNS-related proteins in a single workflow. This represents a four-fold increase from the previous AAIC conference, demonstrating growing adoption of the technology in Alzheimer's research.